Investigating the variables controlling gene silencing at the brain vasculature

Abstract

There are about 190,000 new brain tumour diagnoses annually and the prognosis following a brain tumour diagnosis is less than 18 months survival (Curr Oncol Rep, 2010 12, 26). The current proposal seeks to test the hypothesis that targeting gene silencing to the brain tumour vasculature is a viable glioblastoma treatment strategy. Our aim is to exploit recent findings on nanoparticle adherence to the luminal side of brain endothelial cells (J Raman Microscopy, 2012, 43, 668) to explore the possibility of achieving selective gene silencing of vascular endotheiial growth factor (VEGF) and thus a brain tumour selective anti-angiogenic effect.





References:
[1]

E.J. Chisholm, G. Vassaux, P. Martin-Duque, R. Chevre, O. Lambert, B. Pitard, A. Merron, M. Weeks, J. Burnet, I. Peerlinck, M.-S. Dai, G. Alusi, S.J. Mather, K. Bolton, I.F. Uchegbu, A.G. Schatzlein, P. Baril, Cancer-specific transgene expression mediated by systemic injection of nanoparticles, Cancer Res., 69 (2009) 2955-2962.

[2]

J. Moger, N.L. Garrett, D. Begley, L. Mihoreanu, A. Lalatsa, M. Lozano, M. Mazza, A. Schatzlein, I.F. Uchegbu, Imaging cortical vasculature with stimulated Raman scattering and two photon photothermal lensing microscopy, Journal Raman Spectroscop, 43 (2012) 668-674.

[3]

M. Wang, M. Thanou M, Targeting nanoparticles to cancer, Pharmacol Res. (2010) 62,2,90-99.

[4]

C. Dufes, W.N. Keith, A. Bilsland, I. Proutski, J.F. Uchegbu, A.G. Schatzlein, Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors, Cancer Res., 65 (2005) 8079-8084.

[5]

A. Siew, H. Le, M. Thiovolet, P. Gellert, A. Schatzlein, I. Uchegbu, Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles, Molecular Pharmaceutics, 9 (2012) 14-28.


Biological Areas:

Cell Biology
Biotechnology

BBSRC Area:

Animal disease, health and welfare